anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for preparing a seaweeds based flavour enhancer/seasoning with cardiovascular health promoting, degenerative disease preventing and organ protective properties comprises the steps of pre-treating seaweeds; pulverization or extracting the pre-treated seaweeds using a solvent; with or without the addition of polyphenol rich plants/extracts and other food additives. Further, the present invention also relates to a method for preparing a non-toxic anti-cancer agent and healthcare, oral and topical nutraceutical ingredients for humans and animals. The steps of pre-treating alcoholic extracts derive from plants of the tropical seaweeds, Solanum and Piper spp.; extracting the pre-treated alcoholic extracts of by using a solvent; removing the pre-treated alcoholic extracts of from the used solvent; and concentrating the used solvent to acquire the nutraceutical ingredients. Also provided is a method for preparing a wound healing accelerator and general healthcare, oral and topical nutraceutical ingredients for diabetics and non-diabetics humans and animals. The steps of pre-treating vegetative parts derive from plants of the seaweeds and Arecaceae family; extracting the pre-treated vegetative parts by using a solvent; removing the pre-treated vegetative parts from the used solvent; and concentrating the used solvent to acquire the nutraceutical ingredients.
PURPOSE:To provide an anti-HBV agent containing quercetin or isoquercitrin capable of being readily obtained from a plant such as Houttuynia cordata Thunb. or Gossypium nanking Meyen as an active ingredient, and effective for treating hepatitis B patients. CONSTITUTION:An anti-HBV agent contains quercetin (X is H) or isoquercitrin (X is glucose residue) of the formula (X is H or glucose residue) as an active ingredient. The compound can readily be isolated from the plant and purified. The agent is preferably administered at a dose of approximately 0.01-10 g/adult in the case of oral administration and at a dose of 0.1-1 g/adult in the case of parenteral administration. 17mug/ml of the quercetin has 52% HBVcDNA synthesis-inhibiting activity.
The invention discloses a collagen source natural short peptide for blocking bFGF and application thereof, relating to the technical field of polypeptide synthesis, and the technical key points are as follows: the natural short peptide is derived from Type V collagen and is truncated Type V collagen; the sequences of small polypeptide molecules HBS-P1 and HBS-P3 based on a HEPV core structural domain, HBS-P1 and HBS-P3 are shown in SEQ ID NO.1 and SEQ ID NO.2 respectively; the nucleotide sequences of the HBS-P1 and the HBS-P3 expressed in the prokaryotic expression system are respectively shown as SEQ ID NO.3 and SEQ ID NO. 4. HBS-P1 consists of 45 amino acids and has a molecular weight of 4.3kDa. HBS-P3 consists of 68 amino acids and has a molecular weight of 6.4kDa. The small polypeptide molecules HBS-P1 and HBS-P3 are used for preparing medicines for inhibiting FGF-induced in-vivo and in-vitro angiogenesis and medicines for resisting proliferation of epithelial-like tumor cells. The novel short peptide HBS-P1 has only 45 amino acids, has higher safety and clinical application value, and has the effect of possibly having stronger penetrability to cells and tissues.
The invention relates to methods and compositions for the manufacture and use of novel hydroxy apatite (HA)-calcium binding protein (CaBP) complexes (CaBP-HA complex) that are useful as antigen preparations for immunological assays for the diagnosis, prognosis, and monitoring of mammalian diseases. The CaBP-HA complexes may be manufactured using synthetic HA that is subjected to serum proteins or by harvesting nanobacteria (NB), also called calcifying nano-particles (CNP), from a mammal. The hydroxy apatite is prepared by incubation with appropriate proteins resulting in conformational changes in said bound proteins. Secondary conformational changes occur when said CaBP-HA complex is subjected to enzymes such as transglutaminase thereby creating covalently bound neoepitopes. The CaBP-HA complex may also contain lipopolysaccharide binding protein (LPSBP) providing for anti-CaBP-LPSBP-HA antibodies detection indicative of disease. Detection of anti-CaBP-HA antibodies in a mammal is via enzyme linked immunosorbent assay.
The efficacy of minimal equipment training programs with an emphasis on resistance training has seldom been assessed and compared to traditional strength training. Common training strategies include traditional high-to-moderate load resistance training and low-to-moderate load field training using minimal equipment. The benefit of traditional CT is likely due to the higher loads relative to 1-repetition maximum (1RM) utilized and overall amount of mechanical stress incurred. It is difficult to mimic this loading with minimal equipment training, which is often performed at low loads relative to 1RM. However, one strategy to improve the effectiveness of minimal equipment training may be the addition of blood flow restriction (BFR) training. Due to the relatively low loads (20-70% 1RM) of minimal equipment training, BFR training not only provides athletes with a novel training modality to elicit hypertrophic and strength adaptation but also to augment recovery as a supplemental low-damage, high-volume training method. The research design will allow for the direct comparison of minimal equipment training with and without additional BFR training to periodized CT with regard to changes in outcomes, in particular, ACFT performance.
Asphyxiated neonates often undergo therapeutic hypothermia (TH) to reduce morbidity and mortality. Since both perinatal asphyxia (PA) and TH influence physiology, altered pharmacokinetics (PK) and pharmacodynamics (PD) are expected. Given that TH is the standard of care for PA with moderate to severe hypoxic-ischemic encephalopathy, disentangling the effect of PA versus TH on PK/PD is not possible in clinical settings. However, animal models can provide insights into this matter. The (neonatal) Göttingen Minipig, the recommended strain for nonclinical drug development, was selected as translational model. Four drugs-midazolam (MDZ), fentanyl (FNT), phenobarbital (PHB), and topiramate (TPM)-were intravenously administered under four conditions: control (C), therapeutic hypothermia (TH), hypoxia (H), and hypoxia plus TH (H+TH). Each group included six healthy male neonatal Göttingen Minipigs anesthetized for 24 hours. Blood samples were drawn at 0 (predose) and 0.5, 2, 2.5, 3, 4, 4.5, 6, 8, 12, and 24 hours post drug administration. Drug plasma concentrations were determined using validated bioanalytical assays. The PK parameters were estimated through compartmental and noncompartmental PK analysis. The study showed a statistically significant decrease in FNT clearance (CL; 66% decrease), with an approximately threefold longer half-life (t1/2) in the TH group. The H+TH group showed a 17% reduction in FNT CL, with a 62% longer t1/2 compared with the C group; however, it was not statistically significant. Although not statistically significant, trends toward lower CL and longer t1/2 were observed in the TH and H+TH groups for MDZ and PHB. Additionally, TPM demonstrated a 28% decrease in CL in the H group compared with controls. SIGNIFICANCE STATEMENT: The overarching goal of this study using the neonatal Göttingen Minipig model was to disentangle the effects of systemic hypoxia and TH on PK using four model drugs. Such insights can subsequently be used to inform and develop a physiologically based pharmacokinetic model, which is useful for drug exposure prediction in human neonates.
High tibial osteotomy (HTO) is an established treatment method for medial compartment osteoarthritis with varus knee deformity in a relatively young patient group. Excellent outcomes of HTO have been reported. However, about 10-30% of patients are not satisfied with the results after surgery. After proximal tibial osteotomy, studies on the factors of dissatisfaction have been actively conducted, but studies on the medial and lateral meniscus extrusion, which can be the cause, are insufficient. The relationship between the prolapse of the medial meniscus and articular cartilage is already well known and is known as an important factor in the progression of arthritis. As such, the association between the knee joint with meniscus extrusion and the general knee joint has been studied, but the effect on the clinical outcome after proximal tibial osteotomy has not been studied. Therefore, in this study, the investigators are planning to investigate the differences in clinical outcomes such as the degree and change of medial and lateral meniscus extrusion through non-invasive ultrasound examination before and after surgery in patients who undergo medial open proximal tibial osteotomy.

This study will enroll the patients with knee medial compartment osteoarthritis of the knee joint who undergo open proximal tibial osteotomy. The degree of medial and lateral meniscus extrusion will be measured through ultrasound measurements before and after surgery. Also, demographic factors and radiographic measurements will be also investigated before and after surgery. In addition, preoperative, postoperative 3, 6, and 1 year clinical results including meniscus extrusion will be compared and judged, and the evaluation will be evaluated by an orthopedic surgeon who has not participated in the operation among registered researchers.
OBJECTIVE: Digital self-management programs are increasingly used in the management of osteoarthritis (OA). Little is known about heterogeneous patterns in response to these programs. We describe weekly pain trajectories of people with knee or hip OA over up to 52-week participation in a digital self-management program.
METHODS: Observational cohort study among participants enrolled between January 2019 and September 2021 who participated at least 4 and up to 52 weeks in the program (n = 16 274). We measured pain using Numeric Rating Scale (NRS 0-10) and applied latent class growth analysis to identify classes with similar trajectories. Associations between baseline characteristics and trajectory classes were examined using multinomial logistic regression and dominance analysis.
RESULTS: We identified 4 pain trajectory classes: "mild-largely improved" (30%), "low moderate-largely improved" (34%), "upper moderate-improved" (24%), and "severe-persistent" (12%). For classes with decreasing pain, the most pain reduction occurred during first 20 weeks and was stable thereafter. Male sex, older age, lower body mass index (BMI), better physical function, lower activity impairment, less anxiety/depression, higher education, knee OA, no walking difficulties, no wish for surgery and higher physical activity, all measured at enrolment, were associated with greater probabilities of membership in "mild-largely improved" class than other classes. Dominance analysis suggested that activity impairment followed by wish for surgery and walking difficulties were the most important predictors of trajectory class membership.
CONCLUSIONS: Our results highlight the importance of reaching people with OA for first-line treatment prior to developing severe pain, poor health status and a wish for surgery.
PURPOSE:The titled lipsome, prepared by entrapping a specific face-to-face type diporphyrin metallic complex in a phospholipid, capable of forming an oxygen complex stable in an aqueous phase at room temperature, etc. and reversibly adsorbing and desorbing oxygen by the difference in partial pressure of oxygen, and useful for medical oxygen transporting materials, etc. CONSTITUTION:A metallic porphyrin di(nitophenyl ester), etc. is dissolved in pyridine under heating, and a porphyrin diamino derivative is then added thereto and reacted therewith under heating to afford a face-to-face type porphyrin. The resultant face-to-face type porphyrin is reacted with ferrous chloride to form a complex, which is then reacted with a substituted imidazole expressed by formula I (R1 is H or substituent group; R2 is hydrophobic substituent group; R3 and R4 are H or substitutent group) to give the face-to-face type porphyrin metallic complex expressed by formula II (M is copper or zinc; R is H or substituent group). An egg yolk phosphatidyl chloine is then added thereto and stirred with ultrasonic waves to afford the aimed liposome.
The invention discloses a preparation method for a syringa reticulata var. mandshurica facial mask. The method comprises the following steps: a, filtering a syringa reticulata var. mandshurica stock solution by using diatomite, and performing reduced pressure distillation on a filter liquor at 60-90 DEG C under 200-400Pa for 4-6 hours to obtain distillate; b, cooling the distillate obtained in the step a to 20-30 DEG C, and uniformly mixing the distillate with lemon essential oil according to a weight ratio of 300 to (1-2) to obtain a syringa reticulata var. mandshurica solution; and c, finally heating and dissolving 4-10 parts by weight of glycerine, 1-2 parts by weight of polyvinylpyrrolidone, 40-70 parts by weight of the syringa reticulata var. mandshurica solution and 15-30 parts by weight of de-ionized water, stirring uniformly, cooling, adding 3-10 parts by weight of VC, dissolving, and stirring uniformly to obtain the syringa reticulata var. mandshurica facial mask. The method has the beneficial effects that a preparation process is simple; and the facial mask prepared from natural syringa reticulata var. mandshurica as a raw material and the rest components has a good effect on redness and swelling as well as allergy of skin, does not contain a chemical additive, has no irritation on the skin during use, and is good in water supplement effect.
PURPOSE: Nuclear accumulation of YAP/TAZ promotes tumorigenesis in several cancers, including melanoma. Although the mechanisms underlying the nuclear retention of YAP are known, those underlying the retention of TAZ remain unclear. Our study investigates a novel acetylation/deacetylation switch in TAZ, governing its subcellular localization in melanoma tumorigenesis.
METHODS: Immunoprecipitation/Western blot assessed TAZ protein interactions and acetylation. SIRT5 activity was quantified with enzyme-linked immunosorbent assay. Immunofluorescence indicated TAZ nuclear localization. TEAD transcriptional activity was measured through luciferase reporter assays. ChIP detected TAZ binding to the CTGF promoter. Transwell and wound healing assays quantified melanoma cell invasiveness and migration. Metastasis was evaluated using a mouse model via tail vein injections. Clinical relevance was explored via immunohistochemical staining of patient tumors.
RESULTS: CBP facilitated TAZ acetylation at K54 in response to epidermal growth factor stimulation, while SIRT5 mediated deacetylation. Acetylation correlated with phosphorylation, regulating TAZ's binding with LATS2 or TEAD. TAZ K54 acetylation enhanced its S89 phosphorylation, promoting cytosolic retention via LATS2 interaction. SIRT5-mediated deacetylation enhanced TAZ-TEAD interaction and nuclear retention. Chromatin IP showed SIRT5-deacetylated TAZ recruited to CTGF promoter, boosting transcriptional activity. In a mouse model, SIRT5 overexpression induced melanoma metastasis to lung tissue following the injection of B16F10 melanocytes via the tail vein, and this effect was prevented by verteporfin treatment.
CONCLUSIONS: Our study revealed a novel mechanism of TAZ nuclear retention regulated by SIRT5-mediated K54 deacetylation and demonstrated the significance of TAZ deacetylation in CTGF expression. This study highlights the potential implications of the SIRT5/TAZ axis for treating metastatic melanoma.
Decades of evidence positioned IL-1β as a master regulatory cytokine in acute and chronic inflammatory diseases. Approved biologics aimed at inhibiting IL-1 signaling have shown efficacy but variable safety. More recently, targeting NLRP3 activation, an upstream mediator of IL-1β, has garnered the most attention. Aberrant NLRP3 activation has been demonstrated to participate in the progression of several pathological conditions from neurogenerative diseases to cardio-metabolic syndromes and cancer. Pharmacological and genetic strategies aimed to limit NLRP3 function have proven effective in many preclinical models of diseases. These evidences have lead to a significant effort in the generation and clinical testing of small orally active molecules that can target NLRP3. In this report, we discuss different properties of these molecules with translational potential and describe the technologies currently available to screen NLRP3 targeting molecules highlighting advantages and limitations of each method.
The treatment of postoperative pain continues to be a challenge, particularly after posterior spinal fusions. Many of these patients have been treated with analgesics or other modalities for prolonged periods before choosing the surgical alternative. In addition, the narcotic-based anesthetic required for the procedure may induce postoperative hyper-analgesia. Inadequate treatment of this pain can result in prolonged hospitalization, cardiopulmonary complications, and poor surgical outcome. However, the narcotic treatment of pain is often associated with multiple adverse effects. Multimodal postoperative analgesia has been instituted to reduce pain while limiting the adverse side effects of opioids. Pregabalin has been shown to be efficacious in the management of chronic pain syndromes with limited adverse side effects. Hence, multiple studies have attempted to demonstrate the benefits of including pregabalin in multimodal postoperative pain management. These studies have yielded conflicting results with regard to reduced pain, opioid consumption, and improved outcome. We propose that the addition of pregabalin to acute pain regimen after posterior spinal fusions should reduce narcotic requirements and hence improve outcome by reducing narcoticinduced side effects. Although recent studies have also examined the administration of pregabalin after spinal fusions, this study was conducted with a uniform anesthetic regimen and similar procedure performed by two spine surgeons at one institution. Pain scores were controlled as well as physical therapy milestones to assess whether changes in the pain regimen would affect narcotic consumption, narcotic induced side effects, and length of hospitalization.
This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
NEW MATERIAL:A compound of formula I (R is H or residue of monohydric alcohol; the bond containing dotted line is double bond or triple bond). EXAMPLE:20,20,20-Trifluoroarachidonic acid. USE:An agent for controlling arachidonic acid metabolism. It is effective in preventing the deactivation of the acid by omega-oxidation in living body. PREPARATION:The compound of formula I can be produced by a conventional process comprising a reaction of a fluoroaldehyde of formula II with a Witting reagent having the hydrocarbon chain of formula III and treated with a strong base. The Witting reagent of formula III is preferably the compound of formula IV (R<1> is alkyl, aryl or aralkl; X is halogen).
The HPV vaccine, which has been demonstrated to be an effective method of reducing the risk of developing cervical cancer, is still being underutilized among college students in China. To assess the current status of HPV vaccine hesitancy among college students in Guangdong Province after the COVID-19 outbreak, and to systematically analyze the influencing factors of HPV vaccine hesitancy and construct a prediction model based on the WHO 3Cs model. A cross-sectional web-based survey was conducted in June 2023 among female college students in four cities in Guangdong Province. The data were analyzed using binary logistic regression with a focus on the 3Cs model: Complacency, Convenience, and Confidence. LASSO regression was employed to analyze the variables deemed to be of significance and to construct predictive models. Out of 1399 participants, 86.5% expressed no hesitancy toward HPV vaccination. However, 11.9% exhibited hesitancy, and 1.6% refused vaccination altogether. Factors such as trust in vaccine efficacy, perception of HPV infection risk, price considerations, and constraints like distance or time were significant contributors to hesitancy. Knowledge of the HPV vaccine, socio-demographic characteristics, and the educational level of participants' mothers also played a role in vaccine hesitancy. It is recommended that targeted interventions be implemented within educational institutions with the aim of raising awareness of cervical cancer and HPV vaccines, simplifying the scheduling of vaccination appointments, and increasing affordability through the implementation of strategic purchasing measures or subsidy schemes.
The particularity of some disabled patients, especially those with an autism spectrum disorder, is represented by anxiety, which can range from a slight tension to screaming or even extreme agitation. This behavior can make therapeutic management difficult, both for the patient and the caregiver. This is particularly true for oral health care, where the cooperation of the patient is essential. Conventional behavioral approaches, with implementation of a multitude of adaptive strategies, has a fundamental role to play. With disabled patients, these techniques are most often based on non-verbal or para-verbal communication rather than on linguistic procedures. In this context, an Animal Assisted Intervention could be of major help. The primary outcome is average child anxiety during the session assessed by the Venham scale modified by Veerkamp measured at the end of the third session of care (without animal-assisted therapy).
Participants will receive Ro542-4802/F08 (containing 3% SLS) capsules orally on Day 1 of first intervention period; then Ro542-4802/F14 (containing 12.5% SLS) capsules orally on Day 1 in second intervention period; then Ro542-4802/F07 (containing 25% SLS) capsules orally on Day 1 of third intervention period; followed by Ro542-4802/F03 (containing 50% SLS) capsules orally on Day 1 of the fourth intervention period during both fasted (Part 1) and fed (Part 2) conditions. A washout period of at least 10 days will be maintained between each period.
PCT No. PCT/GB85/00087 Sec. 371 Date Oct. 9, 1985 Sec. 102(e) Date Oct. 9, 1985 PCT Filed Mar. 4, 1985 PCT Pub. No. WO85/03875 PCT Pub. Date Sep. 12, 1985.Existing vaccines against swine dysentery are not very effective. It has now been found that an effective regime of vaccination comprises administering parenterally to pigs a priming dose of killed virulent or pathogenic T. hyodysenteriae effective to stimulate the immune response of the pig to a subsequent dose of a live avirulent or non-pathogenic strain of T. hyodysenteriae and at about the same time or thereafter administering this live strain orally. The invention provides a kit for use in such a method. The live strain is preferably NCTC 11628 deposited as a Budapest Treaty patent deposit.